Talapro-3 could help move Talzenna into earlier prostate cancer.
ApexOnco Front Page
Recent articles
Single, double and even triple-payload ADCs will be presented at the meeting.
The Echelon-3 study seemed doomed, but it just read out positively for overall survival.
New clinical trial entrants include the group’s attempt at targeting Sting, a field that has seen many setbacks.
Tamarack data are a 2024 catalyst, so why has MacroGenics brought forward a follow-on molecule?
BeiGene has a strong presence at this year’s AACR, which features several notable duels.
Projects from the likes of BioNTech, Transgene and Scancell will feature, but still have much to prove.
After beating Darzalex, GSK’s withdrawn anti-BCMA ADC beats Velcade in early multiple myeloma.